Inhibitor of growth (ING)4, member of a gene family encoding potential tumor suppressors, is implicated as a repressor of angiogenesis and tumor growth and suppresses loss of contact inhibition in vitro. Here, we report that ING4 undergoes alternative splicing. Expression analysis identified novel ING4 spliced variant mRNAs encoding proteins devoid of different portions. The ING4 variants were detected in both normal and tumor tissues. The existence of ING4 variants was confirmed by several approaches, including reverse transcriptase-polymerase chain reaction, real-time PCR and in silico experiments. To investigate the functional consequences of alternative splicing the ING4 variant cDNAs were expressed in mammalian cells. Our studies indicated that (i) the ING4 variants do not differ from wild-type in their nuclear localization, interaction with p53 and association to HBO1 complex; and (ii) the ING4-DEx6A variant, devoid of the C-terminal portion, loses the capability to inhibit NF-jB. On the whole our data suggest that alternative splicing could modulate the activity of ING4 tumor suppressor protein.
Introduction
The evolutionary conserved inhibitor of growth (ING) human gene family includes five members (INGs1-5), considered as type II tumor suppressor genes (Feng et al., 2002) . ING1, the founding member, was identified using a strategy designed to discover genes suppressed in cancer cells; the other members of the ING family were identified through sequence homology (Gong et al., 2005) .
The amino-acid sequence alignment of human ING proteins revealed few conserved regions: a Leucin Zipper-like (LZL) motif, probably involved in proteinprotein interaction, located at the N-terminus of all ING proteins but ING1; a bipartite nuclear localization signal (NLS), containing two clusters of basic amino acids; and a C-terminal plant homeo-domain (PHD), a Cys4-His-Cys3 zinc finger motif spanning 50-80 residues, found in many nuclear proteins such as transcription factors and proteins regulating chromatin structure (He et al., 2005; Russell et al., 2006) . ING2 PHD domain interacts with phosphoinositides, thus regulating the capability of ING2 to activate p53 (Gozani et al., 2003) . In a recent report the ING PHD domain has been shown capable to interact with histone H3 di-or tri-methylated at lysine 4 (H3K4me2/3). In particular, with respect to ING2, such interaction results in gene repression (Pena et al., 2006; Shi et al., 2006) .
Functional analysis of the ING family proteins provided a link with p53 signaling pathways, supporting their involvement in cellular processes such as growth arrest, replicative senescence, apoptosis and DNA repair. A physical association between ING proteins and p53 has been reported in different studies. Furthermore, ING proteins may modulate p53 activity by enhancing p53 acetylation at Lys-382 (Nagashima et al., 2001; Kataoka et al., 2003; Russell et al., 2006) .
ING proteins are also involved in the regulation of gene expression through localized chromatin modification; this occurs via association of INGs with the HAT and HDAC enzymatic complexes that regulate histone acetylation (Loewith et al., 2000; Gong et al., 2005; Doyon et al., 2006) .
Several evidences support a tumor suppressor role of ING genes in human cancer. Although ING1 mutations are infrequent, most of them were found in the NLS and PHD domains (Gong et al., 2005) . ING1 downregulation was observed in different tumor types (breast, gastric, esophageal, blood, lung and brain) (Gong et al., 2005) , whereas protein mislocalization was described in tumors of different origin (Nouman et al., 2002) . ING2 expression was reduced in colorectal, hepatocellular carcinoma, prostate, pancreatic, lung cancer and cutaneous melanoma (Nagashima et al., 2001; Lu et al., 2006; Okano et al., 2006) . Allelic loss and reduced expression of ING3 have been also reported (Gunduz et al., 2002; Nagashima et al., 2003) .
The ING4 gene, located at chromosome 12p13.31, consists of eight exons and encodes a 29-kDa protein expressed in multiple human tissues (Garkavtsev et al., 2004; Gunduz et al., 2005; He et al., 2005) . Allelic loss of ING4 locus has been reported in head and neck squamous cell carcinomas and in breast tumors (Kim et al., 2004; Gunduz et al., 2005) . ING4 was also isolated through a screening for genes able to suppress loss of contact inhibition without affecting cellular proliferation (Kim et al., 2004) . Similarly to the other ING family members, ING4 was described to associate with p53 and to upregulate p53-inducible genes ; this is mediated by the bipartite NLS1, also essential for nuclear localization (Zhang et al., 2005) . A second, nonfunctional, NLS2 is located at the C-terminal (Unoki et al., 2006) . A recent study demonstrated a role of ING4 in the regulation of growth of transplanted glioblastoma through a physical association with the p65 (RelA) subunit of NF-kB and subsequent downregulation of NF-kB responsive genes involved in angiogenesis. ING4 mRNA resulted downregulated in gliomas and its expression decreased from lower to higher level of malignancy (Garkavtsev et al., 2004) . More recently, ING4 has been shown to interact with HIF-associated prolyl hydroxylase (HPH)-2, and to regulate the activity of the hypoxia-inducible factor (HIF)-1a transcription factor, thus suppressing the expression of HIF-1a responsive genes under hypoxic conditions (Ozer et al., 2005) . The interaction with HPH-2 requires the ING4 PHD domain; interestingly, such domain has been recently shown involved in the association with histone H3K4me2/3 (Pena et al., 2006; Shi et al., 2006) .
ING4 would regulate gene expression by localizing histone-modifying enzymes to sites of active transcription, and interacting with various transcription factors. Recently, ING4 protein was found associated to the HAT complex containing HBO1, hEafS and JADE1/2/3 proteins (Zhou et al., 2005; Doyon et al., 2006; Russell et al., 2006) . Different mutations in the ING4 transcript were detected in several cancer cell lines, and for all of them a loss of function effect has been proposed. The prevalent mutation was a deletion encompassing 12 nucleotides (379-390) within the NLS1; different mis-sense mutations were also detected (Kim et al., 2004) .
On the basis of the possibility that ING4 can be inactivated by point mutations and small deletions, we planned the analysis of expression and mutational screening of ING4 in papillary thyroid carcinoma (PTC); for this neoplasia, which represents the main interest of our group, a role for tumor suppressor genes has not yet completely established. The evidence of novel ING4 mRNA variants prompted us to extend the study to a collection of normal tissues. Here, we report the expression of different ING4 splicing variants in all the tissues analysed and a preliminary functional characterization.
Results
Analysis of ING4 expression in human tissues: evidence of different mRNA variants Inactivating mutations of the ING4 gene have been recently reported in several human tumor cell lines. The prevalent mutation was the deletion of nucleotides 379-390, corresponding to amino acids 127-130 (KGKK) within the NLS1 (Kim et al., 2004) , and henceforth indicated as D4AA. RNAs from two normal thyroids and five PTCs were analysed by reverse transcriptasepolymerase chain reaction (RT-PCR) using primer combination Ex1F/Ex8R, which amplifies the entire ING4 coding sequence ( Figure 1 ). As control of the T47D breast carcinoma cell line, shown previously to contain the wild-type and the D4AA-ING4 transcripts (Kim et al., 2004) , was used. The expected 750 bp PCR product was detected by agarose gel electrophoresis ( Figure 1a ) and subjected to direct nucleotide sequencing. The sequences obtained matched with ING4, however, they presented regions of superimposition, suggesting existence of multiple ING4 transcripts not visible in the ethidium bromide staining shown in Figure 1a . To clarify this issue we performed RT-PCR with the Ex1F/Ex8R primer combination on a larger RNA collection (Table 1) Figure 1b . In all the samples the majority of the clones carried the expected 750 bp insert; noteworthy other clones, whose frequency is variable among the different cases, carried shorter inserts (Table 1) . Nucleotide sequencing of randomly selected plasmids with the expected insert size identified clones carrying ING4-WT, and other carrying the ING4-D4AA sequences. The availability of these clones allowed us to design and validate the PCR approach shown in Figure 2 , capable to discriminate between ING4-WT and ING4-D4AA mRNAs. The Ex1F/Ex8R primer combination reacts with both ING4-WT and ING4-D4AA and amplifies respectively fragments of 750 and 738 bp, displaying similar electrophoretic migration. Primer D4AAF, containing the nucleotides lacking in ING4-D4AA mRNA, reacts only with wild-type and, in combination with primer Ex8R, produces a 384 bp fragment. Multiplex PCR employing the three oligonucleotides amplifies the 750 and 384 fragments on the wild-type, but only the 738 fragment on the D4AA template. By this approach clones carrying the D4AA deletion were identified based on the absence of the 384 bp PCR fragment (see Figure 2) . Nucleotide sequencing of sample clones confirmed the multiplex PCR results. Data are summarized in Table 1 , and indicate that (i) clones carrying the D4AA deletion were isolated from 14 out of 16 mRNA analysed; (ii) the D4AA deletion is not restricted to tumor tissues; (iii) the frequencies of the two mRNAs are variable, however the ING4-WT transcript is prevalent in all the tissues analysed; this also includes the T47D cell line, shown previously to contain both ING4 transcripts, without indication of their relative frequencies; and (iv) other ING4 mRNA variants are present in all the tissues analysed.
Structure of novel ING4 variants
To characterize the novel ING4 variants we sequenced several pTargeT clones carrying short inserts (Table 1) . BLAST comparison with ING4 sequence present in GenBank (accession number AF156552.1) allowed the identification of four different transcripts (Figure 3a ) respectively lacking exons 2, 3 and 6 (entirely or in part), most likely produced by alternative splicing, and named ING4-DEx2, -DEx3, -DEx6A and -DEx6B (Genebank accession numbers: 866218, 861385, 861387, 866220). The ING4-DEx2 mRNA lacks exon 2 (72 nucleotides); it encodes a 225-amino-acid protein containing a novel asparagine residue in position 13 encoded by the AAC codon formed by exon 1/3 junction. The ING4-DEx3 mRNA lacks exon 3 (167 nucleotides); the deletion causes translation frameshift and premature stop of the protein within exon 4. The ING4-DEx3 protein consists of 51 amino acids, the first 36 of which are identical to wild-type. The ING4-DEx6A mRNA lacks the entire exon 6 (148 nucleotides); this causes translation frameshift and premature termination within exon 7; the ING4-DEx6A protein contains 179 amino acids, the last 12 different from wild-type. The ING4-DEx6B mRNA lacks the first 109 nucleotides of exon 6 and arises from the use of a cryptic splice site; this causes frameshift and premature termination within the remaining exon 6 sequences. The ING4-DEx6B protein contains 172 amino acids, the last five different from wild-type. Figure 2 Identification of pTargeT-ING4 clones carrying the D4AA cDNA. Top: Schematic representation of ING4-WT mRNA structure. In the enlarged portion, the region encompassing the 12 nucleotides (bold) deleted in D4AA is shown; the corresponding four deleted amino acids are indicated above the nucleotide sequence. Primer positions are indicated. Middle: Size of the expected PCR products obtained using each primer pair on ING4-WT and -D4AA templates are reported. (Bottom) Randomly selected pTargeT-ING4 recombinant clones (lanes 1-10) were subjected to multiplex-PCR using primers Ex1F, D4AAF and Ex8R; products were separated on 2% agarose gel. Size of the amplified fragments is indicated. M, size markers (100 bp; Promega).
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As shown in Figure 3a in the ING4-DEx2 protein the C-terminal moiety of the LZL motif, the NLSs and the PHD domains are retained; the ING4-DEx3 protein contains the N-terminal moiety of the LZL motif and is devoid of both NLSs and PHD domains; the ING4-DEx6A and -DEx6B proteins retain the LZL motif and the NLS1, but lack the PHD domain and NLS2.
Validation of ING4 variant expression
The presence of the ING4 variants was further validated by two different approaches. First, a series of human RNAs was analysed by RT-PCR using primer combination Ex1F/Ex5R and Ex4F/Ex8R, amplifying two overlapping fragments on ING4-WT template ( Figure 3a) . In all the samples analysed PCR amplification with Ex1F/Ex5R produced three fragments of 431, 359 and 264 bp, corresponding to ING4-WT, -DEx2 and -DEx3 mRNA, respectively. Analogously, in the amplification with Ex4F/Ex8R three fragments of 448, 339 and 300 bp, corresponding to ING4-WT, -DEx6B and -DEx6A, were detected in several samples (Figure 3b ). This analysis provided also information about the relative expression level of each ING4 isoform: the wild-type mRNA is prevalent, in keeping with the results of clone analysis above reported.
In a complementary approach we attempted the selective and simultaneous amplification of wild-type and alternatively spliced ING4 mRNAs. For each variant we performed multiplex PCR experiments using a common primer (reacting with both wild-type and alternative spliced ING4 mRNAs) and two unique primers, located within the deleted exon or the new exon junctions, and therefore reacting with the wild-type or the alternatively spliced mRNAs, respectively (see To demonstrate further the expression of ING4 splicing variants we performed real time PCR assays. TaqMan assays specific for ING4-D4AA, -DEx2, -DEx3, -DEx6A and -DEx6B variants and total ING4 mRNA were designed (see Material and methods). A collection of RNAs from normal tissues and two tumor cell lines (Hela and T47D) was used. Analysis performed in standard conditions showed that variants -D4AA, -DEx2, -DEx3 are expressed in all the samples analysed; the highest expression was detected in the brain ( Figure 5 , left panel). In these conditions expression levels of -DEx6 variants resulted below the sensibility of the instrument. To improve detection level, the abovedescribed assay was performed using higher amounts of HeLa, T47D and brain RT reactions. In this case, we were able to detect the expression of both ING4 -DEx6A and B variants (Figure 5, right panel RTs from the indicated samples were subjected to PCR amplification using primer pairs Ex1F/Ex5R (top) and Ex4F/Ex8R (middle). As control, pTargeT clones carrying ING4-WT or variant (DEx2, DEx3, DEx6A and DEx6B) cDNAs are shown. Products were separated on 2% agarose gel. Size of PCR products is indicated. As control, the housekeeping GAPDH mRNA was amplified (bottom). M, size markers (100 bp; Promega). N, negative control (no template). 
Functional characterization of ING4 protein variants
To investigate functional consequences of ING4 alternative splicing we performed a biochemical characterization of the resulting proteins. pTargeT recombinant clones carrying the ING4 cDNA variants in the sense orientation with respect to the vector CMV promoter were selected by sequence analysis. All the cDNA clones contain the ING4 ATG start codon, but not the upstream sequences. However, the presence of an adenine in position -3, provided by the vector sequences, would predict an efficient protein expression, based on Kozak consensus (Kozak, 1987) . To investigate the efficiency of such ATG as an initiation codon, HEK293T cells were transiently transfected with ING4-WT, -D4AA and -DEx2 expression plasmids and cell extracts were analysed by Western blot with anti-ING4 antibodies.
As the antibody epitope (located within exon 6 encoded sequences) is completely or partially lost in ING4-DEx3, -DEx6A and -DEx6B, these variants were not included in the analysis. As shown in Figure 6a , ING4-WT, -D4AA and -DEx2 cDNAs produced the expected proteins of 29, 28.5 and 26 kDa, respectively, thus demonstrating the efficiency of the initiation codon.
To detect ING4-DEx3, -DEx6A and -DEx6B variants we inserted all the ING4 cDNAs into pcDNA3.1/ mycHis vector, containing the myc epitope and transfected them into HEK293T cells. Western blot analysis with anti-myc antibodies revealed the expression of ∆Ex6A ∆Ex6B total RQ RQ Figure 5 Expression levels of ING4 splice variants in HeLa and T47D cell lines and various tissues. Expression levels were examined by real time PCR using custom TaqMan assays; b2microglobulin RNA was used for normalization. Expression levels were normalized with respect to HeLa cells. In the left panel, 5 ng of retro-transcribed RNA were used as template; in the right panel, 25 ng of retrotranscribed RNA were used. RQ, relative level of gene expression.
ING4 alternative splicing G Raho et al ING4-myc-WT, -D4AA, -DEx2, -DEx6A and -DEx6B proteins with the expected molecular weight (Figure 6c) . On the contrary, we were not able to detect the expression of the ING4-myc-DEx3 protein (predicted molecular weight of 5.5 kDa) (not shown). As this protein contains only the N-terminal 36 amino acids of ING4-WT, it was not further analysed. ING4 has been shown previously to display nuclear localization driven by its bipartite NLS1, a region also important for interaction with p53 (Zhang et al., 2005) . A second nuclear localization signal (NLS2), located at the C terminus, has been recently shown not required for ING4 nuclear localization (Unoki et al., 2006) . To investigate the cellular localization of the novel ING4 variants immunofluorescence and cell fractionation experiments in ING4-myc transfected cells were performed. Immunofluorescence experiments with anti-myc 9E10 antibodies (Figure 6b, top) showed that all the variant ING4 proteins are localized in the nucleus, similarly to the wild-type. As control, the lack of reactivity of mock-transfected cells, and the cytoplasmic localization of TFG-myc protein (Greco et al., 1995) are shown. Moreover, Western blot analysis of nuclear and cytoplasmic extracts from ING4-myc-transfected HEK293T cells showed that all the ING4 variants retain the capability to enter the nucleus (Figure 6b , bottom). The detection of ING4 variants in the nucleus suggests that none of the lacking regions contribute to the nuclear localization of ING4.
We next investigated the capability of ING4 variants to interact with p53. HEK293T cells were transiently transfected with ING4-myc constructs, and the cell extracts were incubated with GST-murine p53 fusion protein or GST as control. As shown in Figure 5c , ING4 (Garkavtsev et al., 2004) . We confirmed this effect in our system by NF-kB transactivation assays, performed in HeLa cells transfected with the NF-kB luciferase reporter vector in combination with p65NF-kB and ING4-WT cDNAs (data not shown). To assess the effect of ING4 protein variants on NF-kB-dependent transactivation, we performed the above-described transactivation assay by cotransfecting p65 with ING4 variants. Owing to the similarity of ING4-DEx6A protein, ING4-DEx6B was not included in this analysis. The effect of the ING4 variants on NF-kB activity was normalized for the effect of the wild-type. As reported in Figure 6d , no significant variation of NF-kB-dependent transactivation was observed in cells expressing ING4-D4AA and -DEx2, thus indicating that the deleted regions are not involved in NF-kB inhibition. On the contrary, significant increase in the NF-kB activity with respect to ING4-WT was observed in cells expressing ING4-DEx6A variant. This indicates that ING4-DEx6A loses ING4-WT ability to inhibit NF-kB, suggesting that regions encoded by exon 6 are responsible for such function. This is consistent with previous data showing that deletion mutants of ING4, lacking C-terminal moiety, are not able to inhibit p65NF-kB (Garkavtsev et al., 2004) . The capacity of ING4-WT to inhibit NF-kB activity is not affected by the simultaneous expression of ING4-DEx6A (data not shown), thus suggesting that the variant is unlikely to exert a dominant-negative effect in this context.
ING4 has been recently identified as a subunit of HAT complex containing HBO1 (Doyon et al., 2006) . We investigated whether this capability is retained by ING4 variants. To this end we performed coimmunoprecipitation experiments in cells expressing the ING4-myc proteins. As shown in Figure 6e all the ING4 variants were detected in HBO1 immunocomplexes.
In summary, our data indicate that the ING4 variants do not differ from the wild-type protein in nuclear localization, interaction with p53 and HAT/HBO1 complex formation, whereas the ING4 inhibition of p65NF-kB activity was lost in ING4-DEx6A variant.
Discussion
ING4 is a member of the oncosuppressor ING gene family and participates to a variety of cellular functions, such as apoptosis, cell-cycle regulation, chromatin remodeling and regulation of gene expression (Russell et al., 2006) . A large body of evidence documents ING4 involvement in human cancer through different mechanisms. Loss of heterozygosity has been reported in head and neck squamous cell carcinomas and in breast tumors (Kim et al., 2004; Gunduz et al., 2005) . ING4 was found downregulated in gliomas and the extent of downregulation correlated with level of malignancy (Garkavtsev et al., 2004) . Different ING4 mutations, most likely resulting in inactive proteins, have been recently described in human cancer cell lines. The most frequent mutation was a deletion of four amino acids (here called D4AA) within the NLS1 produced by alternative splicing (Kim et al., 2004) . On the basis of notion that ING4 can be inactivated by mutations, we planned to investigate the expression and mutational status of ING4 in PTCs, a tumor type for which a role for tumor suppressor genes has not been completely established.
Expression analysis by RT-PCR, cloning of PCR products and characterization of plasmid clones identified the D4AA and several novel ING4 variants in tumor as well as in normal thyroids; therefore, we undertook the expression analysis and characterization of ING4 variants in different normal human tissues. In all the samples analysed the ING4-WT mRNA was prevalent with respect to the other variants, as deduced by the characterization of plasmid clones. The frequency of ING4-D4AA was determined by a mutation-specific PCR approach and nucleotide sequencing and resulted variable among samples, but always lower than wildtype. Real-time PCR data showed that ING4-D4AA variant was expressed in all the normal tissues analysed, displaying higher expression level in brain, kidney and thyroid. The presence of ING4-D4AA in normal tissues is in contrast with the data by Kim et al. (2004) , who detected this variant in several human cancer cell lines but not in the IMR90 normal lung fibroblasts, and proposed it as a loss of function, tumor-specific alteration. Such discrepancy might be ascribed to the different source of normal and tumor RNAs (surgical specimens versus cell lines), and the different number of plasmid clones analysed in the two studies. The large number of normal tissues and the different approaches used in the present work makes us confident in concluding that ING4-D4AA variant is expressed in normal tissues. It is worth noting that, in agreement with Kim et al. (2004) data, we detected both ING4-WT and -D4AA in the T47D breast cancer cell line used as control.
Most recently, when this paper was under revision, new ING4 splicing variants have been described. Wobble splicing at the exon 4-5 boundary generates slightly different mRNAs, encoding proteins devoid of 1-4 amino acids (Tsai and Lin, 2006) . These variants partially overlap with ING4-D4AA, although none of them is perfectly matching. Interestingly, all the wobble variants were detected in normal tissues. Using a different approach, Unoki et al. (2006) documented the expression of the same variants in normal and tumor tissues; moreover, they showed functional differences among ING4 variants.
Our study identified four ING4 novel variants named ING4-DEx2, -DEx3 and -DEx6A and -DEx6B, respectively lacking exons 2, 3 and 6 (entirely or in part). These variants, produced by alternative splicing, were detected in all the RNA samples analysed. The existence of the different ING4 variants was corroborated by several experimental approaches. Multiplex PCR using a common primer as well as primers specific for wild-type or variant RNAs detected the different ING4 transcripts in a series of normal human tissues. Real-time PCR experiments specific for each ING4 variant further confirmed their expression in a collection of normal tissues and in HeLa and T47 cell lines. Finally, EST sequences matching the novel exon junctions of the ING4 variants were present in public database.
ING4 protein is involved in numerous cellular processes, and the contribution of the different domains is only in part understood. The NLS1 domain is responsible for ING4 nuclear localization and interaction with p53 Zhang et al., 2005) . The PHD domain, a zinc finger motif present in many nuclear proteins (Bienz, 2006) , is involved in interaction with HPH-2 (Ozer et al., 2005) and H3K4me2/3 (Pena et al., 2006; Shi et al., 2006) , thus linking ING4 to regulation of gene expression. A deletion mutant lacking the C-terminal 40 amino acids, including the PHD domain, is unable to interact with p65, thus abrogating the inhibitory effect of ING4 on NF-kB activity (Garkavtsev et al., 2004) . Analogously, a mutant devoid of the C-terminal portion resulted inactive in suppressing loss of contact inhibition (Kim et al., 2004) .
To address the functional consequences of exon skipping on ING4 activity, we expressed the ING4-variant cDNAs in mammalian cells and investigated their cellular localization, interaction with p53 and effect on NF-kB activity. The ING4-DEx3 was excluded from this analysis, because it encodes a small protein containing only 36 amino acids of the wild-type.
All the ING4 variants retain the nuclear localization and the ability to interact with p53. These functions are ascribed to the NLS1 and, in particular to amino acids 142-146 (RARSK) (Zhang et al., 2005) . This region is retained by all the variants, including the ING4-D4AA, which carries a deletion of amino acids 127-130 (KGKK) within the NLS1 domain. A partially overlapping deletion (129-132, KKKG) abrogates the nuclear localization (Unoki et al., 2006) , suggesting that KG residues 130-132, rather than KK 129-130, are required for ING4 proper cellular localization. This is in keeping with a previous report showing that mutations of residues 129-130 do not affect nuclear localization of ING4 (Zhang et al., 2005) .
Our data confirmed the inhibitory effect of ING4-WT on NF-kB activity, a mechanism driven by interaction of ING4 with p65. ING4-DEx2 and -D4AA displayed effect similar to wild-type, suggesting that the deleted regions are not involved in the regulation of NF-kB activity. The ING4-DEx6A protein loses the ability to inhibit NF-kB. Our data are in keeping with previous study showing that the deletion of the last 40 amino acids abrogates the effect of ING4 on NF-kB activa tion. Interestingly, the region lacking in ING4-DEx6A contains the PHD domain, involved in the binding to HPH-2, and H3K4me2/3 (Ozer et al., 2005; Pena et al., 2006; Shi et al., 2006) . Thus, alternative splicing producing ING4-DEx6 variants could impair some important functions of ING4 and modulate its contribution to specific pathways. In keeping with this concept our data demonstrate that ING4-DEx6A is capable to interact with the HBO1/HAT complex; however, owing to the lack of H3K4me2/3-binding site, it is most likely inactive in chromatin acetylation.
The analysis performed in this study did not show any difference between ING4-WT and ING4-DEx2 variant; however, we cannot exclude that other ING4 functions might be affected. The search is complicated by the lack of information about the role of ING4 region deleted in ING4-DEx2, which contains a LZL motif within a region conserved among the different family members.
Accumulating evidence has shown that alternative splicing is associated with cancer (Venables, 2004; Kalnina et al., 2005) , and it also represents a novel mechanism for the inactivation of tumor suppressor genes (Huiping et al., 2002; Kaufmann et al., 2002) . Alternative splicing also has been described for ING genes. In particular human ING1 gene encodes four proteins, differing at the N-terminus and exerting distinct functions (He et al., 2005) . In addition, multiple variants of ING1 and ING2 have been identified in Xenopus laevis . While this paper was under revision, new ING4 variants produced by alternative splicing at the exon 4-5 boundary have been described (Tsai and Lin, 2006; Unoki et al., 2006) . These reports, together with our data, strongly support the notion that ING4 functions may be differentially affected by alternative splicing.
Although several important issues remain to be addressed, such as ING4 splicing regulation in different physiological and/or pathological conditions, and the functional consequences of ING4 alternative splicing, our work report novel ING4 alternative splicing forms affecting important domains, suggesting a mechanism for ING4 modulation.
Materials and methods

RNA and RT-PCR
Total human RNA from normal and tumor tissues, collected from patients undergoing surgery in our Institute, was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). Brain RNA was from Ambion (Huntingdon, United Kingdom). One microgram of RNA was reverse-transcribed using Superscript II Reverse Transcriptase (Invitrogen) with random examers, according to manufacturer's protocol. Quality of RT reactions was monitored by PCR amplification of the housekeeping gene glyceraldehyde-3 phosphate dehydrogenase (GAPDH) using primers 5 0 -GAAGGTGAAGGTC GGAGTC-3 0 and 5 0 -GAAGATGGTGATGGGATTTC-3 0 . After a denaturation at 941C for 3 min, 33 PCR cycles were performed (941C for 30 s, 551C for 30 s, 721C for 30 s), followed by a final extension at 721C for 5 min.
The entire coding region of ING4-WT (nt 1-750) was amplified using the primers: Ex1F (5 0 -ATGGCTGCGGG GATGTATTTGGAAC-3 0 , exon 1, nt 1-25), and Ex8R (5 0 -CTATTTCTTCTTCCGTTCTTGGGAGCAG -3 0 , exon 8, nt 750-722). The two overlapping fragments of the coding region of ING4-WT, respectively of 431 (nt 1-431) and 448 bp (nt 302-750), were amplified using the primer pairs: Ex1F, and Ex5R (5 0 -CGAGCACGAGCAGCTTTCTTCTCC-3 0 , exon 5, nt 431-408); Ex4F (5 0 -ACACAGACCTGGCCCGTTTT GAGG-3 0 , exon 4, nt 302-325) and Ex8R. In both cases annealing temperature was 571C.
Multiplex RT-PCR for simultaneous amplification of ING4-WT and ING4 variant mRNAs were performed using the primers combinations reported below. Coamplification of ING4-WT and -DEx2 mRNAs was performed using Ex5R common primer in combination with Ex2F (5 0 -GTATT GAAAACCTTCCCTTTGAAT-3 0 , exon 2, nt 38-61) and DEx2F (5 0 -TGGAACATTATCTGGACAACC -3 0 , spanning exon 1, nt 20-37 and exon 3, nt 110-112, underlined); annealing temperature was 611C. To coamplify the ING4-WT and -DEx3 variant, Ex5R (common primer) together with Ex3F (5 0 -ACCTGAAGGCTGAAATTGACAAG-3 0 , exon 3, nt 110-132) and DEx3F (5 0 -CCAAAGAACAGAGGGTG GACA-3 0 , exon 2, nt 96-109 and exon 4, nt 277-283 underlined) were used; annealing temperature was 631C. ING4-WT and -DEx6A mRNAs were coamplified using Ex4F common primer in combination with Ex6R (5 0 -CTGGTGACAAAGGC AATAGGT-3 0 , exon 6, nt 609-589) and DEx6AR (5 0 -CCA CTCAATGGAACAGTGCGC-3 0 , exon 7, nt 663-649 and exon 5, nt 500-495 underlined); annealing temperature was 651C. In all the cases after a denaturation at 941C for 3 min, 37 PCR cycles were performed (941C for 1 min, annealing at primer specific temperature for 1 min, 721C for 2 min) followed by a final extension at 721C for 7 min.
PCRs were performed in a total volume of 20 ml containing single strand cDNAs prepared from 50 to 100 ng of total RNA, 1 Â PCR buffer, 1.0 mM MgCl 2 , 200 mM each dNTP, 0.5 mM each primer and 0.25 U of AmpliTaq-Gold polymerase (Applied Biosystem, Foster City, CA, USA). For coamplification of ING4-WT and ING4-variant mRNAs the above described 1.0 mM of the common and 0.5 mM of each unique primer were used.
The primers used in this study were synthesized by MWG Biotech (Ebesberg, Germany). Reverse transcription and PCRs were performed using Gene Amp PCR System 9700 (Applied Biosystem).
ING4 expression plasmids
pTargeT-ING4 constructs were generated by cloning PCR products obtained with primers Ex1F and Ex8R into pTargeT mammalian expression vector (Promega, Madison, WI, USA). Recombinant clones were identified by EcoRI digestion, which releases the inserts. pTargeT-ING4 clones carrying the D4AA deletion were identified by multiplex PCR with primers Ex1F, Ex8R and D4AAF (5 0 -AGCTCTTCCAGCAAAGGCAA AAAG-3 0 , exon 4, nt 367-390). PCR conditions used were: denaturation at 941C for 10 min followed by 25 PCR cycles (941C for 1 min, 571C for 1 min, 721C for 2 min) and a final extension at 721C for 5 min. PCRs were prepared as described above. An aliquot of the PCR products and/or the restriction reactions was revealed by ethidium bromide staining in agarose gel.
To 0 ) for ING4-DEx6B. After denaturation at 941C for 5 min 30 PCR cycles were performed (941C for 1 min, 571C for 1 min, 721C for 1 min), followed by final extension at 721C for 5 min.
PCR products were digested with XhoI and HindIII restriction enzymes and inserted into the pcDNA3.1/mycHis(À)A mammalian expression vector (Invitrogen) digested with the same restriction enzymes. The resulting ING4-myc constructs carry the myc epitope at the C-terminal end.
All the pTargeT-ING4 and ING4-myc constructs were sequenced using the 3100 Genetic Analyzers (Applied Biosystems).
Real-time PCR
Real-time PCR was performed using TaqMan assay. Five or 25 nanograms of retro-transcribed RNA were used as template. The specific primers and sequences for each variant have been designed by Custom TaqMan(R) Gene Expression Assay Service and are reported in the table below:
Reactions were performed in a total volume of 15 ml using TaqMan Universal Mastermix and TaqMan assay (Applied Biosystems). After an initial incubation at 951C for 10 min, 40 two-step cycles were performed at 951C for 15 s and 601C for 1 min. Human b2 microglobulin (Applied Biosystems) was used to normalize the assays in different tissues.
Bioinformatic analysis
A BLAST search for homology in human EST databases (http://www.ncbi.nlm.nih.gov/dbEST/) was performed. As query sequences of 60-70 nucleotides around the novel exon junction of each ING4 variant were used. Immunoprecipitaion, Western blot analysis, recombinant protein production and in vitro binding assay HEK293T cells transfected with ING4 constructs were lysed in lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid, 0.5% NonidetP-40) supplemented with protease inhibitors (Roche), phenylmethylsulfonyl fluoride and Na 3 VO 4 . For coimmunoprecipitation experiments, 1 mg of clarified extracts was preincubated with Protein A-sepharose for 1 h; precleared extracts were then incubated with anti-HBO1 antibodies (Santa Cruz Biotech, CA, USA) for 3 h, washed three times with lysis buffer and boiled in Laemmli sample buffer. GST-p53(murine) fused protein (kindly provided by Dr D Delia, Istituto Nazionale Tumori, Milan, Italy) was produced in BL21 Escherichia coli strain by inducing with 0.56 mM isopropylb-D-thiogalactoside for 3 h at 301C and purified with glutathione Sepharose (Amersham Bioscience, Uppsala, Sweden).
Cell cultures and transfections
For pull-down experiments 800 mg of clarified extracts were precleared with glutathione Sepharose for 1 h then incubated with 5 mg of GST-p53 or GST conjugated to glutathione Sepharose for 90 min, washed three times with lysis buffer and boiled in Laemmli sample buffer.
Protein samples were separated on 12.5% SDS-PAGE, transferred onto nitrocellulose filters and immunoblotted with specific antibodies. Anti-myc (clone 9E10) and anti-ING4 antibodies were purchased from Roche and Rockland (Gilbertsville, PA, USA), respectively. Immuno-reactive bands were visualized using horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (Amersham).
Luciferase assay
HeLa cells (5 Â 10 4 ) were transfected with FuGene6 (Roche, Manheim, Germany) in 24-well plates with 100 ng of pNF-kBLuc (Stratagene, La Jolla, CA, USA), 50 ng of pRL-TK (Promega, Madison, WI, USA), 20 ng of CMV-p65 plasmid (kindly provided by Dr AJ Capobianco, The Wistar Institute, Philadelphia, PA, USA) in combination with 280 ng of pTargeT-ING4 splice variant constructs. Forty-eight hours after transfection, cell extracts were prepared and reporter gene activity was determined by Dual-Luciferase Reporter Assay (Promega). The experiments were performed in triplicates. Data are reported as the ratio between Firefly and Renilla luciferase units and expressed as fold over ING4 WT effect on p65-NF-kB activity.
Immunofluorescence assay HeLa cells (5 Â 10 4 ) were plated on glass coverslips and transiently transfected with 150 ng of the indicated ING4-myc construct. The day after transfection, cells were fixed with 3% paraformaldehyde, 2% sucrose, and stained with anti-myc 9E10 monoclonal antibodies (Roche), followed by FITCconjugated secondary antibodies (1:200; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Coverslides were mounted with Vectashield containing DAPI (Vector Laboratories, Inc., Burlingame, CA, USA). Stained cells were observed with microscope Nikon Eclipse E1000; images were captured with Nikon DXM digital camera.
